CBFA2T3 as a Key Prognostic Biomarker in Lung Adenocarcinoma: Insights from Comprehensive Analysis and Validation.

IF 1.6 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemical Genetics Pub Date : 2025-08-13 DOI:10.1007/s10528-025-11224-x

Jianbo Xiao, Kexin Luo, Meihan Liu, Haiyang Zhao, Yuanze Cai, Yan Gui, Hongpan Zhang

{"title":"CBFA2T3 as a Key Prognostic Biomarker in Lung Adenocarcinoma: Insights from Comprehensive Analysis and Validation.","authors":"Jianbo Xiao, Kexin Luo, Meihan Liu, Haiyang Zhao, Yuanze Cai, Yan Gui, Hongpan Zhang","doi":"10.1007/s10528-025-11224-x","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is a common and highly lethal malignancy globally, predominantly comprising non-small cell lung cancer (NSCLC), accounting for 80-85% of lung cancer cases. Lung adenocarcinoma (LUAD) represents the predominant subtype of NSCLC and is characterized by challenging early diagnosis and poor prognosis. Studies have implicated CBFA2T3 expression in treatment outcomes and prognosis across various cancers, yet its specific mechanisms remain under investigation. Analysis of TCGA data revealed a negative correlation between CBFA2T3 expression and tumor growth, suggesting that lower CBFA2T3 levels are associated with poorer outcomes in patients with LUAD. Our research identifies CBFA2T3 as a therapeutic target and potential prognostic indicator in LUAD, closely linked to immune cell infiltration and key immune regulatory markers. A model integrating CBFA2T3-regulated immune-related genes was constructed to predict the prognosis and immunotherapy response of patients with LUAD. Our findings were validated using GSE31210 and IMvigor210 datasets. qPCR and WB experiments on clinically collected samples confirmed reduced CBFA2T3 expression in LUAD. Online analysis using the Kaplan‒Meier plotter website confirmed a correlation between reduced CBFA2T3 expression and poorer prognosis in patients with lung cancer. Ultimately, our study identifies CBFA2T3 as a pivotal prognostic biomarker and potential therapeutic target for managing LUAD.</p>","PeriodicalId":482,"journal":{"name":"Biochemical Genetics","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Genetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s10528-025-11224-x","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is a common and highly lethal malignancy globally, predominantly comprising non-small cell lung cancer (NSCLC), accounting for 80-85% of lung cancer cases. Lung adenocarcinoma (LUAD) represents the predominant subtype of NSCLC and is characterized by challenging early diagnosis and poor prognosis. Studies have implicated CBFA2T3 expression in treatment outcomes and prognosis across various cancers, yet its specific mechanisms remain under investigation. Analysis of TCGA data revealed a negative correlation between CBFA2T3 expression and tumor growth, suggesting that lower CBFA2T3 levels are associated with poorer outcomes in patients with LUAD. Our research identifies CBFA2T3 as a therapeutic target and potential prognostic indicator in LUAD, closely linked to immune cell infiltration and key immune regulatory markers. A model integrating CBFA2T3-regulated immune-related genes was constructed to predict the prognosis and immunotherapy response of patients with LUAD. Our findings were validated using GSE31210 and IMvigor210 datasets. qPCR and WB experiments on clinically collected samples confirmed reduced CBFA2T3 expression in LUAD. Online analysis using the Kaplan‒Meier plotter website confirmed a correlation between reduced CBFA2T3 expression and poorer prognosis in patients with lung cancer. Ultimately, our study identifies CBFA2T3 as a pivotal prognostic biomarker and potential therapeutic target for managing LUAD.

查看原文本刊更多论文

CBFA2T3作为肺腺癌的关键预后生物标志物：来自综合分析和验证的见解

肺癌是全球常见的高致死率恶性肿瘤，以非小细胞肺癌（NSCLC）为主，占肺癌病例的80-85%。肺腺癌（LUAD）是非小细胞肺癌的主要亚型，其特点是早期诊断困难，预后差。研究表明CBFA2T3表达与各种癌症的治疗结果和预后有关，但其具体机制仍在研究中。TCGA数据分析显示CBFA2T3表达与肿瘤生长呈负相关，提示较低的CBFA2T3水平与LUAD患者预后较差相关。我们的研究发现CBFA2T3是LUAD的治疗靶点和潜在预后指标，与免疫细胞浸润和关键免疫调节标志物密切相关。构建整合cbfa2t3调控的免疫相关基因的模型，预测LUAD患者的预后和免疫治疗反应。使用GSE31210和IMvigor210数据集验证了我们的发现。临床采集样本的qPCR和WB实验证实LUAD中CBFA2T3表达降低。Kaplan-Meier绘图仪网站的在线分析证实了肺癌患者CBFA2T3表达降低与预后较差之间的相关性。最终，我们的研究确定了CBFA2T3是治疗LUAD的关键预后生物标志物和潜在治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemical Genetics 生物-生化与分子生物学

CiteScore

3.90

自引率

0.00%

发文量

133

审稿时长

4.8 months

期刊介绍： Biochemical Genetics welcomes original manuscripts that address and test clear scientific hypotheses, are directed to a broad scientific audience, and clearly contribute to the advancement of the field through the use of sound sampling or experimental design, reliable analytical methodologies and robust statistical analyses. Although studies focusing on particular regions and target organisms are welcome, it is not the journal’s goal to publish essentially descriptive studies that provide results with narrow applicability, or are based on very small samples or pseudoreplication. Rather, Biochemical Genetics welcomes review articles that go beyond summarizing previous publications and create added value through the systematic analysis and critique of the current state of knowledge or by conducting meta-analyses. Methodological articles are also within the scope of Biological Genetics, particularly when new laboratory techniques or computational approaches are fully described and thoroughly compared with the existing benchmark methods. Biochemical Genetics welcomes articles on the following topics: Genomics; Proteomics; Population genetics; Phylogenetics; Metagenomics; Microbial genetics; Genetics and evolution of wild and cultivated plants; Animal genetics and evolution; Human genetics and evolution; Genetic disorders; Genetic markers of diseases; Gene technology and therapy; Experimental and analytical methods; Statistical and computational methods.